Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Myeloid 2CNS 1

Conditions

Neuroblastoma 2Rhabdomyosarcoma 1Recurrence 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Desmoplastic Small Round Cell Tumor 1

Interventions

Temozolomide 23Bevacizumab 18Cyclophosphamide 9Carboplatin 7Lomustine 6Irinotecan 63-Iodobenzylguanidine 6Topotecan 5Radiotherapy 5Filgrastim 5Radiosurgery 4Nivolumab 4Everolimus 4Etoposide 4Drug Therapy 4Busulfan 4sonidegib 3pembrolizumab 3olaparib 3fludarabine phosphate 3fludarabine 3cemiplimab 3antineoplaston AS 2-1 3antineoplaston A10 3Vincristine 3Thiotepa 3Sirolimus 3Melphalan 3IL13-PE38 3Antilymphocyte Serum 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Cyclosporins × CNS × Clear all
NCT00874315 2015-10-16

Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.

Nationwide Children's Hospital

Phase 2 Withdrawn
CNS

Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡